Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML4AVX)

• Drug Name: PMID27841045-Compound-156 Drug Info
• Cross-matching ID:
  PubChem CID: 5281294
  ChEBI ID: CHEBI:7734
  CAS Number: CAS 484-76-4
  TTD Drug ID: DML4AVX

Molecule-Related Drug Atlas

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Gout	FA25	Approved	[3]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[4]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[5]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[7]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[8]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[9]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[10]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[11]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[1]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[12]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[12]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[12]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[13]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[2]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[14]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[15]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[16]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[17]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[18]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[19]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[20]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[21]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[22]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[13]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[23]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[21]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[24]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[22]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[21]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[19]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[25]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[22]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[26]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[13]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[21]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[14]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[21]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[25]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[2]

References

• [1] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [2] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [3] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [4] Clinical pipeline report, company report or official report of Takeda (2009).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [6] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [7] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [8] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [9] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [10] Clinical pipeline report, company report or official report of Teijin Pharma.
• [11] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [12] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [13] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [14] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [15] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [16] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [17] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [18] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [19] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [20] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [21] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [22] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [23] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [24] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [25] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [26] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.